Press Releases Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			Pre-market 08:30:30
2.35 ^USD	-8.56%		2.385	+1.49%

06-24	Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-11	Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06-14	BU
Revance to Participate in Upcoming Investor Conferences	05-28	BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY for the Treatment of Cervical Dystonia	05-10	AQ
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update	05-09	BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia	05-09	BU
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024	05-02	BU
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-15	AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	04-15	AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	04-12	BU
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03-28	AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03-27	BU
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	03-07	AQ
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	03-04	BU
Revance Announces Proposed Public Offering of Common Stock	03-04	BU
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	02-28	BU
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024	02-21	BU
Revance to Participate in Upcoming Investor Conferences	02-21	BU
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®	02-02	BU
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference	02-01	BU
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook	01-08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Press Releases

Filters